β-肾上腺素能受体通路基因变异既是早产儿视网膜病变的风险因素也是保护因素
本研究为观察性病例对照靶向遗传分析,纳入伴或不伴早产儿视网膜病变(ROP)的早产儿及足月对照,分为发现队列和验证队列。对ADRβ通路20个基因靶向测序发现5个基因的10个单核苷酸变异与ROP相关,PRKAR1A变异可能为保护因素,RAPGEF3变异可能为风险因素。
要点
- ADRβ通路5个基因的10个单核苷酸变异与ROP相关(P < .05)。
- PRKAR1A中最显著的单核苷酸变异与ROP相关(P = .001),可能为保护因素。
- RAPGEF3的3'非翻译区多个变异与ROP相关(P < .05),可能为风险因素。
核心结论
- PRKAR1A的单核苷酸变异可能代表ROP的保护因素,而RAPGEF3的单核苷酸变异可能代表ROP的风险因素。
- 作者认为这些新发现的风险因素经多中心验证后可能成为预测和预防严重ROP的有价值工具。
研究设计与样本
- 观察性病例对照靶向遗传分析,纳入伴ROP的早产儿(n = 30)、不伴ROP的早产儿(n = 34)及足月对照(n = 20),分为发现队列和验证队列。
- ROP依据国际早产儿视网膜病变分类标准(ICROP)定义。
- 在发现队列中对ADRβ通路的20个基因进行靶向测序,并用验证队列对部分发现的ROP相关变异行聚合酶链反应(PCR)/限制性内切酶分析验证。
主要发现
- 发现队列在ADRβ通路的20个基因中检出543个双等位基因变异。
- 5个基因(PRKAR1A、RAPGEF3、ADCY4、ADCY7和ADCY9)中的10个单核苷酸变异与ROP相关(P < .05)。
- 最显著的单核苷酸变异位于PRKAR1A(P = .001)。
- 位于RAPGEF3的3'非翻译区的多个变异也与ROP相关(P < .05)。
- 对RAPGEF3的3'非翻译区行PCR/限制性内切酶分析在方法学上验证了上述发现。
关键数值与推荐
- ROP依据国际早产儿视网膜病变分类标准(ICROP)定义。
- ADRβ通路5个基因的10个单核苷酸变异与ROP相关(P < .05),最显著者位于PRKAR1A(P = .001)。
- RAPGEF3的3'非翻译区多个变异与ROP相关(P < .05)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者指出这些新发现的风险因素需要多中心验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: There is strong evidence that genetic factors influence retinopathy of prematurity (ROP), a neovascular eye disease. It has been previously suggested that polymorphisms in the genes involved in β-adrenergic receptor (ADRβ) pathways could protect against ROP. Antagonists for the ADRβ are actively tested in clinical trials for ROP treatment, but not without controversy and safety concerns. This study was designed to assess whether genetic variations in components of the ADRβ signaling pathways associate with risk of developing ROP. DESIGN: An observational case-control targeted genetic analysis. METHODS: A study was carried out in premature participants with (n = 30) or without (n = 34) ROP and full-term controls (n = 20), who were divided into a discovery cohort and a validation cohort. ROP was defined using International Classification of Retinopathy of Prematurity criteria (ICROP). Targeted sequencing of 20 genes in the ADRβ pathways was performed in the discovery cohort. Polymerase chain reaction (PCR)/restriction enzyme analysis for some of the discovered ROP-associated variants was performed for validation of the results using the validation cohort. RESULTS: The discovery cohort revealed 543 bi-allelic variants within 20 genes of the ADRβ pathways. Ten single-nucleotide variants (SNVs) in 5 genes including protein kinase A regulatory subunit 1α (PRKAR1A), rap guanine exchange factor 3 (RAPGEF3), adenylyl cyclase 4 (ADCY4), ADCY7, and ADCY9 were associated with ROP (P < .05). The most significant SNV was found in PRKAR1A (P = .001). Multiple variants located in the 3'-untranslated region (3'UTR) of RAPGEF3 were also associated with ROP (P < .05). PCR/restriction enzyme analysis of the 3'UTR of RAPGEF3 methodologically validated these findings. CONCLUSION: SNVs in PRKAR1A may represent protective factors whereas SNVs in RAPGEF3 may represent risk factors for ROP. PRKAR1α has previously been implicated in retinal vascular development whereas the RAPGEF3 product has a role in the maintenance of vascular barrier function, 2 processes important in ROP. Multicenter validation of these newly discovered risk factors could lead to valuable tools for predicting and preventing the development of severe ROP.
引用
- Paradis H, Werdyani S, Zhai G, et al. Genetic Variants of the Beta-Adrenergic Receptor Pathways as Both Risk and Protective Factors for Retinopathy of Prematurity. Am J Ophthalmol. 2024. PMID: 38224928. doi:10.1016/j.ajo.2023.12.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。